Systemic cyclosporine (CSA) was given to 43 high-risk keratoplasty patients (vascularisation in three or four quadrants and >16 stromal vessels): 14 received CSA for 12 months (long CSA group) and 29 for a 4-6 month period (short CSA group). A group of 37 similar high-risk keratoplasty patients received no CSA (no CSA group). In the no CSA group 27 (73%) grafts had rejection episodes compared with 21 (48.8%) in the combined CSA group (p = 0.025). Rejection was reversed in only 23.3% of the no CSA group, compared with 50% and 87.5% in the short (p = 0.06) and long (p = 0.002) CSA groups respectively. Com pared with the no CSA group, overall graft survival was better in both the short (p = 0.019) and long (p = 0.0056) CSA groups. This improvement resulted from both a reduction in the incidence, and an increase in the reversal rate, of rejection episodes. The improvement continued after stopping CSA, suggest ing that some immunological privilege had been re established. Acuities of 20/40 or better were achieved by 44.8% and 50% of eyes in the short and long CSA groups respectively, compared with 13.5% of eyes in the no CSA group.
In keratoplasty the commonest cause of graft failure is rejection.1,2 In high-risk keratoplasty the failure rate from rejection is between 60% and 90%, depending on the criteria for defining high risk. [2] [3] [4] [5] [6] Despite the use of corticosteroids in high doses both topically and systemically, rejection in high-risk keratoplasty is not reliably prevented. Other recent attempts to improve graft prognosis in high-risk cases by tissue matching7 or by the use of topical cyclosporine (CSA) have not led to a significant improvement.
We have reported on the use of systemic CSA in high-risk keratoplastY', 9 and have shown that it improves graft survival by reducing the incidence of failure from irreversible graft rejection? If rejection can be prevented during the early post-operative period, a time when rejection is more likely to occur, then later some degree of immunological privilege may be re-established allowing CSA to be safely withdrawn. Our studies have shown that a 12 month course of systemic CSA is more effective in this regard than the shorter 4-6 month course of therapy. 9 CSA is a potent immunosuppressant agent with a high degree of specificity for T lymphocytes. It suppresses cell-mediated reactions and in transplantation it is thought to prevent the early stages of antigenic sensitisation and the resulting proliferation of immunocompetent T cells.lO Therefore, CSA should prevent rejection episodes from occurring. Our studies indicated that only 1 of 43 patients had an irreversible graft rejection while taking CSA, but a larger number of grafts developed reversible rejection episodes. In high-risk keratoplasty it is not known whether systemic CSA reduces the incidence of rejection episodes or whether the incidence remains high but CSA influences the outcome by making the treat ment of rejection episodes more successful. This present study investigates these aspects of CSA therapy and examines graft survival to determine whether the beneficial effects of CSA continue after therapy is stopped.
Although rejection remains the commonest cause of graft failure in high-risk keratoplasty, associated ocular damage may lead to graft failure from other causes such as glaucoma, tear film abnormalities or recurrent scarring. If CSA prevents failure from rejection there is the possibility that failure from other causes will become more of a problem. This present study investigates these aspects by analysing graft failure from all causes and documenting the final visual acuity, in a group of high-risk kerato plasty patients given systemic CSA. The results are compared with those in a group of high-risk keratoplasty patients who did not receive CSA.
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PATIENTS AND METHODS
The patients in this prospective study are the same cohort as those reported in a previous study. 9 All were high-risk keratoplasty patients: defined as having three or four quadrants of superficial and deep corneal vascularisation with the total number of vessels reaching the proposed donor site exceeding 16. Many of them had had previously rejected corneal grafts and all had visual acuities of less than 20/200 in the affected eye. Patients were allocated to a treatment group according to the visi ? n in the other eye. CSA was offered only to patIents who were either uniocular or had bilateral corneal disease, with the exception of 3 patients who had a seeing contralateral eye but required binocular vision for their employment. Patients with a good contralateral eye were not offered CSA but received a graft with standard treatment; these grafts were used as a comparison in this study (no CSA group). The n � mber of previous grafts in each group is shown m Table I and the aetiology of the original  corneal disease is shown in Table II .
Forty-three patients were given CSA; at the beginning of the study CSA was given for 12 months but because of our initial success it was felt that the length of treatment could be reduced to economise and prevent potential side-effects. Consequently the remaining patients were treated with CSA for 4-6 months. Fourteen patients received CSA for 12 months (long CSA group) and 29 patients received the drug for 4-6 months (short CSA group). In both groups the dose of CSA was administered twice daily ?y mouth, except for the first dose, which was given mtravenously at the time of surgery. An initial loading dose of 15 mg/kg per day was given for 2 days followed by 7.5 mg/kg per day for 2 days; thereafter the dose was adjusted to maintain therapeutic blood levels. The method used by our laboratory to estimate CSA blood levels changed a number of times during this study. Initially serum levels were measured, but at present whole blood values are preferred. The current method used is the specific whole blood method 11 and the therapeutic range of our laboratory is a trough CSA level of 130-250 /-Lg/l. We attempt to keep blood levels at the lower end of the therapeutic range, and at present a value of between 130 and 170 /-Lg/I is aimed for; the usual dose to achieve this is approximately 3-4 mg/kg per day. During the early post-operative period 29.6 (6-63) 26.7 (7-49) 52.8 (14--82) blood C�A levels, together with serum chemistry, were estImated twice weekly. When the blood CSA levels became stabilised, usually at 3 or 4 weeks, the fre <;l uency of the t � sts .
was reduced. This CSA dosage regImen was mamtamed for the duration of the treatment period.
A group of 37 patients who had similar high-risk corn � as but who had unilateral disease only and were not gIVen CSA, received topical corticosteroids alone (no CSA group).
All the patients in this study were healthy with no serious systemic disease. Those patients receiving <:SA u � derwen� a full blood and metabolic investiga tIon, � Ith partIcular attention being given to the detectIOn of renal and hepatic disease. The kerato plasty techniques were identical for all patients; donor grafts were between 7.5 and 8.5 mm and were 0.5 mm larger than the recipient bed. Donor corneas were preserved as corneosc1eral discs in culture medium (M.K. or KSol solution) at 4°C. A number of patients had a simultaneous extracapsular cataract � xtraction with the placement of a posterior chamber mtraocular lens. All surgery was performed by the author and tissue matching of donor and recipient was not undertaken. A viscoelastic substance was used to protect donor endothelium and to dissect any iris adhesions. A 10/0 nylon suture was used to secure the graft using interrupted or continuous sutures or a combination of both. The anterior chamber was re f ? rm � d . wi�h balanced salt solution, and subconjunc tIval mJectIOns of gentamicin 20 mg and betametha sone (Celestone) 2 mg were given at completion of surgery.
All patients were given topical dexamethasone 0.1 % drops 4 times daily and betamethasone 0.1 % ointment at night. The drops were reduced slowly over the ensuing months and stopped at 6 months unless persistent inflammation required extended therapy. The ointment was usually stopped after 2 weeks. A rejection episode was diagnosed when an eye with a previously clear, thin graft became inflamed with: flare and cells in the anterior chamber, keratic precipitates limited to the donor endothelium, and thickening of the graft either diffusely (probable rejection 16 ) or in the form of an advancing rejection line (definite rejection 16 ). Stromal infiltration without epithelial disease was also considered to be a probable rejection episode. The treatment of rejec tion consisted of hourly dexamethasone 0.1 % drops and a subconjunctival injection of 2 mg betametha sone (Celestone). Eyes with a history of herpes simplex keratitis were also treated with topical antiviral medication. In severe cases of endothelial rejection oral prednisone 60 mg daily was given in addition to the topical medication. Treatment was continued until the inflammation subsided and was then gradually withdrawn. Later in the series a 500 mg intravenous pulse of methylprednisolone was substituted for the oral corticosteroids. A graft was deemed irreversibly rejected when it remained thickened and oedematous with severe visual loss despite maximal medical therapy.
In the first part of this study the incidence of graft rejection was studied regardless of whether the reaction was subsequently reversed. Statistical ana lysis was performed using the log-rank method with the end-point being the commencement of any graft rejection episode. The number of rejection episodes The end-point is the commencement of a rejection episode.
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that were reversed by treatment in the three groups was analysed using chi-squared or Fisher's tests.
In the second part of the study graft failure from any cause was studied. The end-point in the survival analysis was the commencement of a rejection episode in a graft that became irreversibly rejected or failure from any other cause. Failure from another cause was defined as a graft complication causing a loss of vision to an acuity of 20/60 or less; the end point in the statistical analysis was the time when vision dropped to this level. Graft survival was compared by log-rank analysis and the Cox propor tional hazards model.
RESULTS
The number of grafts that had one or more rejection episodes is shown in Table III. In the no CSA group 27 (73%) of the 37 grafts had a rejection episode, compared with 21 (48.8%) of the 43 grafts in the combined CSA group; the difference is significant (p = 0.025). When the total CSA group is subdivided into short and long CSA groups the number of grafts that started to reject was 15 (51.7%) and 6 (42.6%) respectively. There is no statistical difference in survival between the two CSA groups. When survival is compared with the no CSA group, neither the short CSA group (p = 0.099) nor the long CSA group (p = 0.055) reach a level of statistical significance. Both the mean and median time to the first rejection episode were shorter in the no CSA group. Fig. 1 shows actuarial survival curves of the three treatment groups; the end-point of survival in these graphs is the commencement of the first rejection episode. Rejection-free survival was better for grafts in the long CSA group compared with grafts in the short CSA group; both CSA groups showed improved survival compared with the no CSA group.
The total numbers of rejection episodes in the three groups are shown in Table IV (note that some patients had more than one rejection episode). The treatments given for the rejection episodes are shown in Table V. In the no CSA group a total of 30 episodes occurred, giving a mean number of 0.81 per graft; of these 30 episodes only 7 (23.3%) were reversed. In the short CSA group, 18 episodes occurred giving a mean value of 0.62 per graft; 9 (50%) of these episodes were reversed with treat ment. In the long CSA group there were 8 rejection episodes, giving a mean of 0.57 per graft; 7 (87.5%) of these episodes were reversed. In the total CSA group there was a statistically better chance of the rejection episode being reversed by treatment, compared with the no CSA group (p ::: 0.009). Taking the two CSA groups separately, the improved rejection reversal rate was also seen in the long CSA group (p ::: 0.002) but the improvement failed to achieve statistical significance in the short CSA group (p ::: 0.06), when compared with the no CSA group. To assess whether this improved rejection reversal rate is maintained after the CSA therapy is stopped, the two CSA groups were analysed before and after cessation of treatment (Table VI) . It can be seen that the reversal rates while on CSA are high: 75% and 100% for the short and long CSA groups respectively. After treatment is stopped the reversal rates drop to 42.9% and 80% for the short and long CSA groups respectively, but both are better than the rate in the no CSA group (23.3%). However, only the results of the long CSA group achieve statistical significance (p ::: 0.03) compared with the no CSA group. Although irreversible rejection was the common est cause of graft failure, a number of grafts failed from other causes (Table VII) , failure being defined as a visual acuity of 20/60 or worse. The number of grafts that failed for reasons other than rejection are as follows: no CSA group 5 (13.5%), short CSA group 3 (8.1 %) and long CSA group 4 (28.6%). Fig.  2 shows survival curves of the three groups, the end point being irreversible graft failure from rejection or failure from any other cause. There was a signifi cantly improved survival of grafts in the short CSA group (p ::: 0.019), long CSA group (p ::: 0.0056) and combined CSA group (p ::: 0.0036) when compared with the no CSA group. There was no difference between the two CSA groups in terms of survival (p ::: 0.43). Using the Cox proportional hazards model a difference in survival between the CSA groups exists: at any point in time the hazard of a graft in the short CSA group becoming a failure is only 50.2 % that of a graft in the no CSA group; in the long CSA group the hazard is only 25.2% compared with the no CSA group. The final visual acuities of the eyes in the three groups is shown in Table VIn and diagrammatically in Fig. 3 . Acuities of 20/40 or better were achieved by 44.8% and 50% of eyes in the short and long CSA groups respectively. This compared with only 13.5% of eyes in the no CSA group. The number of eyes achieving 20/60 to 20/200 acuity was similar in the three groups. However, 70.3% of eyes in the no CSA group had acuities of less than 20/200, compared with 37.9% and 35.7% in the short and long CSA groups respectively.
DISCUSSION
The definition of high-risk in this study, namely three or four quadrants involved with at least 16 vessels passing over the proposed graft site, is stricter than other studies 7 that define high-risk as two or more quadrants of vascularisation and/or a previously rejected graft in the affected eye. The failure rate in the no CSA group from rejection alone was 62.2 % and from all causes was 75.7%; the final figure is comparable to failure rates of between 60% and 90% in other studies of high-risk keratoplasty ? -6 In high risk patients, blind from corneal disease, these high failure rates do not offer much hope for the prospect of vision.
Without CSA the major cause of graft failure in high-risk keratoplasty remains rejection. In a pre vious paper 9 it was shown that systemic CSA effectively prevents graft failure from irreversible graft rejection, especially if treatment is given for 12 months. This present study shows that CSA achieves this result by two actions. Firstly, CSA reduces the number of rejection episodes, as shown by the improved survival of CSA-treated grafts when the commencement of a rejection episode was used as an end-point. Secondly, in CSA-treated grafts the rejection episodes were more effectively reversed compared with the no CSA group. In both respects the outcome of grafts treated with CSA for 12 months was better. It could be expected that while on CSA treatment any rejection episode is more easily reversed because the patient is taking two immuno suppressant drugs (CSA and corticosteroids) whereas patients in the no CSA group are only being given one (corticosteroids). However, even after CSA was stopped the rejection reversal rates remain higher in the CSA-treated patients; possibly because of small numbers, statistical significance was demonstrated only in the long CSA group. The improved survival of grafts, which is maintained after cessation of CSA treatment, indicates that some degree of immunological privilege may have been re established. Early in the study, rejection episodes that did not appear to be severe were treated with topical corticosteroid drops and a subconjunctival steroid injection. These episodes invariably progressed and, despite the addition of oral corticosteroids at a later stage, the grafts all failed from the rejection episode (Table V) . The regimen was then changed and all patients with rejection episodes were given systemic steroids when they presented. Initially this was in the form of oral prednisone 60 mg daily but later in the study this was replaced by a single intravenous injection of 500 mg methylprednisolone. Because patients in the no CSA group tended to reject earlier, more of these patients were treated by topical steroids alone, and conversely more of the CSA groups were treated with intravenous methylpredni solone. The three treatment regimens used for rejection may have influenced the results because the grafts treated with intravenous methylpredniso lone appeared to have fared better -a finding reported by us previouslyP All rejecting grafts treated only by local corticosteroids failed, regard less of whether they were treated with CSA. Rejecting grafts in the long CSA group treated with oral steroids or with intravenous methylpredni solone appeared to be more effectively reversed than those in the short CSA group, which in turn fared better than rejecting grafts in the no CSA group. This finding is in agreement with the statement made earlier that in CSA-treated grafts the rejection episodes were more effectively reversed, especially in grafts treated with CSA for 12 months.
Other non-immunological causes of graft failure such as recurrent herpetic keratitis and persistent epithelial defects in dry eyes are important and need to be considered . In the long CSA group, in which irreversible rejection was more effectively prevented, the failure rate from non-immunological causes was higher. It would seem, therefore, that by preventing rejection other diseases may be given the opportu nity to become causes of graft failure. Despite this, the survival of CSA-treated grafts, and especially those in the long CSA group, remained statistically better than the no CSA group, taking failure from any cause as the end-point. This improved survival was reflected by the improved final visual acuity results found in the two CSA groups, both of which were substantially better than those of the no CSA group. It should be noted that the follow-up of the long CSA group was longer than for the other two groups, theoretically giving more time for late complications to arise.
The trial was not masked and therefore a patient's treatment group was known to the observers. However, it is unlikely that bias in assessing graft clarity was introduced as the end-points were clearly evident. Grafts that irreversibly rejected invariably developed severe rejection episodes resulting in significant endothelial loss and final corneal thick ness measurements in excess of 700 f.Lm centrally. In the patients with non-immunological failure the end point was clearly defined as a best visual acuity of 20/60 or worse. The diagnosis was made clinically and in those grafts that had associated ocular inflammation no other evidence of rejection, such as a rejection line, keratic precipitates or graft oedema from endothelial loss was present.
CSA is a potent immunosuppressant drug and careful pre-operative systemic investigations and post-operative monitoring are essential to minimise the potential dangers which can arise from its use. Nephrotoxicity,12.13 hepatotoxicit�4 and hyperten sion15 are known complications of CSA use. In addition the suppression of T cell function may lead to infections or to re-activation of an existing infection. The complications from the use of CSA in this cohort of patients were few and have been discussed previously. 9 One patient in the short CSA group developed a TB abscess in the neck, presumably from a re-activation of an undiagnosed inactive lesion; specific TB therapy was commenced and cyclosporine stopped at 2 months. Another patient in the same group developed an intractable pruritic rash and treatment was stopped at 1 month. The grafts from both patients irreversibly rejected: the results were uncensored and are included as failures from rejection while on CSA. Other side effects were less severe and did not require cessation of treatment. One patient who was mildly hyperten sive required additional therapy and 4 patients had an increase in their serum creatinine levels to outside the normal range, but all returned to normal when the dosage of CSA was reduced. Two female patients complained of hirsutism, which in 1 patient became apparent at 4 months and in the other at 7 months; in both the condition reverted to normal on cessation of treatment. Apart from 1 case of hirsutism all the complications occurred within the first few months of treatment. The longer period of treatment in the long CSA group did not give rise to additional side effects, and after 6 months monitoring was reduced to monthly intervals. The low complication rate in this study was possibly due to the good general health of the patients and also because the dosage of CSA used was kept to a minimum by maintaining the blood CSA levels at the lower end of the therapeutic range. The risks of using systemic CSA are therefore justified in high-risk keratoplasty patients who are blind from their disease, are healthy, and who are also willing to comply with treatment and monitoring regimens.
